2-((4-Bromophenyl)(hydroxy)methylene)malononitrile

In the established synthetic route to pirtobrutinib, a malononitrile-derived intermediate undergoes cyclocondensation with an appropriately substituted hydrazine species to form the N-trifluoromethyl-substituted pyrazole core, which is central to the biological activity of the drug. This hydroxy(methylene)malononitrile derivative functions as the activated Michael acceptor/malononitrile component that enables construction of the heterocyclic scaffold that ultimately becomes part of the pirtobrutinib molecule. 2-((4-Bromophenyl)(hydroxy)methylene)malononitrile serves as a key synthetic intermediate in the multi-step synthesis of the active pharmaceutical ingredient pirtobrutinib, a non-covalent BTK (Bruton tyrosine kinase) inhibitor.